Merck & Co (MRK) Earnings Date & Reports

Key Takeaways

• Merck reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year (4% excluding foreign exchange), beating analyst estimates.
• Adjusted (non-GAAP) earnings per share came in at $2.49, well above consensus expectations of roughly $2.08–$2.12.
• The KEYTRUDA oncology franchise generated $8.6 billion (up 6%), including $830 million from the newer injectable formulation KEYTRUDA QLEX.
• Newer products added momentum, with WINREVAIR sales surging about 93% to $694 million and GARDASIL rising 14% to nearly $2 billion.
• Merck raised and narrowed its full-year 2026 outlook to revenue of $66.8–$67.3 billion and adjusted EPS of $2.77–$2.82.
• GAAP (Generally Accepted Accounting Principles) EPS declined to $2.04 from $2.32 a year earlier, reflecting higher investment and a one-time licensing charge.
• For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Discover automated trade ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Merck's quarterly report is a closely watched signal for the broader pharmaceutical sector, because it reveals how the company is managing the eventual loss of exclusivity on its flagship cancer drug KEYTRUDA, whose key patents begin expiring in 2028. Investors are tracking whether newer medicines such as KEYTRUDA QLEX, WINREVAIR, and OHTUVAYRE can offset generic erosion in legacy products like JANUVIA and BRIDION. Third-quarter results delivered evidence that the diversification strategy is working, while management also updated full-year guidance. The beat, combined with a raised profit outlook, helped reinforce confidence in Merck's ability to generate growth beyond its blockbuster franchise.

Reported Results

Merck posted total worldwide sales of $18.1 billion in the third quarter of 2026, an increase of 5% year over year, or 4% excluding the impact of foreign exchange. The figure topped Wall Street consensus estimates, which clustered around $17.2–$17.3 billion.

On the bottom line, adjusted earnings per share (EPS, or profit divided by shares outstanding) reached $2.49, exceeding consensus expectations of roughly $2.08–$2.12. GAAP diluted EPS was $2.04, down from $2.32 a year earlier, reflecting higher operating expenses tied to pipeline investment and product launches, plus a $0.12 per-share one-time charge from a global license agreement with SciBrunch.

Segment highlights included a 6% rise in KEYTRUDA-family sales to $8.6 billion, a 93–94% surge in WINREVAIR to $694 million, a 14% increase in GARDASIL to about $2 billion, and a 4% rise in Animal Health revenue to roughly $1.68 billion. Management noted that approximately $550 million of third-quarter growth reflected favorable customer purchase timing that is expected to partly unwind in the fourth quarter.

Merck also raised its full-year 2026 outlook, narrowing revenue guidance to $66.8–$67.3 billion and lifting adjusted EPS guidance to $2.77–$2.82, up from a prior range of $2.66–$2.76.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking earnings-driven moves like Merck's, the AI Screener offers a structured way to identify comparable setups and monitor momentum across the healthcare sector.

Market Reaction and Investor Sentiment

Investors responded positively to the results. Following the announcement, Merck shares moved higher, with reports pointing to gains of roughly 2% to nearly 5% in early trading and after-hours activity. The combination of a top-and-bottom-line beat, strength in KEYTRUDA QLEX, and an upgraded full-year profit forecast appeared to outweigh concerns about rising operating expenses and a year-over-year decline in GAAP earnings. Sentiment was further supported by management's commentary around clinical milestones presented at the ESMO oncology conference, which reduced perceived risk in the late-stage pipeline. The modest miss in Animal Health revenue did not meaningfully dampen the broader upbeat tone.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching how quickly Merck can sustain the launch trajectory of newer products while preparing for KEYTRUDA's eventual patent expirations. KEYTRUDA QLEX, the under-the-skin version of the drug, reached a record $830 million in quarterly sales, and management has framed patient switching to this formulation as a key lever for protecting oncology revenue over time.

Cost trends also warrant attention. Operating expenses rose in the quarter, driven by investments in launches and the early- and late-stage pipeline. Merck indicated that underlying operating expenses are expected to increase at a mid-to-high single-digit rate, reflecting confidence in the expanding product portfolio. The company also flagged a roughly $550 million purchase-timing benefit that is expected to largely unwind in the fourth quarter.

Additional catalysts include the FDA's acceptance of a biologics license application for sac-TMT in certain endometrial cancer patients, with a decision date set for mid-2027, as well as continued international launches of WINREVAIR and CAPVAXIVE. Meanwhile, generic competition for JANUVIA and BRIDION and softer vaccination trends remain headwinds to monitor. As always, these factors will shape how the market evaluates Merck's ability to deliver durable growth beyond its current blockbuster lineup.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations